Autolus Therapeutics Ltd (AUTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) has a cash flow conversion efficiency ratio of -0.600x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.32 Million) by net assets ($108.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Autolus Therapeutics Ltd balance sheet quality to measure how much of total assets are equity-financed.
Autolus Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Autolus Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore AUTL debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Autolus Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Autolus Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Huakong Seg Co Ltd
SHE:000068
|
0.070x |
|
XMax Inc.
NASDAQ:XWIN
|
-0.140x |
|
Dare Technology Co Ltd
SHE:000910
|
0.003x |
|
Shandong Meichen Science & Technology Co Ltd
SHE:300237
|
0.063x |
|
Beijing Jingyeda Technology Co Ltd
SHE:003005
|
-0.012x |
|
Archer Ltd.
LSE:0RBA
|
0.017x |
|
Maha Energy AB (publ)
ST:MAHA-A
|
-0.038x |
|
Valhi Inc
NYSE:VHI
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Autolus Therapeutics Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Autolus Therapeutics Ltd (AUTL) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $178.13 Million | $-283.57 Million | -1.592x | -229.79% |
| 2024-12-31 | $427.32 Million | $-206.27 Million | -0.483x | +63.04% |
| 2023-12-31 | $111.47 Million | $-145.59 Million | -1.306x | -247.32% |
| 2022-12-31 | $298.67 Million | $-112.31 Million | -0.376x | +0.04% |
| 2021-12-31 | $313.32 Million | $-117.86 Million | -0.376x | +32.91% |
| 2020-12-31 | $210.03 Million | $-117.76 Million | -0.561x | -40.79% |
| 2019-12-31 | $254.84 Million | $-101.48 Million | -0.398x | -216.06% |
| 2018-12-31 | $205.14 Million | $-25.85 Million | -0.126x | 0.00% |
| 2018-09-30 | $205.14 Million | $-25.85 Million | -0.126x | -9.83% |
| 2017-12-31 | $142.60 Million | $-16.36 Million | -0.115x | +64.25% |
| 2016-12-31 | $30.69 Million | $-9.85 Million | -0.321x | -99.85% |
| 2015-12-31 | $20.71 Million | $-3.33 Million | -0.161x | -- |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more